View Author
patient angioplasty cardiogenic shock occlusion restenosi group <0ยท001 mortality infarction follow-up country artery difference diameter study shock stenosi 30- day mortality trial cardiogenic outcome procedure group 1 patients subtotal angiography follow-up angiography angioplasty procedure intervention percutaneous transluminal table event treatment analysis lumen diameter frequency lumen 1- year mortality month 30- transluminal group 2 patients baseline characteristic result reocclusion baseline characteristics catheterisation systolic blood pressure lumen diameter stenosis percutaneou cilazapril disease subtotal stenoses angiographic effect marcator cardiol revascularisation reference location figure therapy lesion benefit factor blood heart 6 months subtotal stenosis pressure 1 year 30 days january resource adjustment duration definition angiogram surgery angina
2 Most Recent Publications
|
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial
(Article)
Holmes Jr, D.R. Califf, R.M. Berger, P.B. Bates, E.R. Simoons, M.L. White, H.D. Thompson, T.D. Topol, E.J. Werf, F.J.J. van de |
1997-01-20
|
|
Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR).
(Article)
Berger, P.B. Holmes Jr, D.R. Ohman, E.M. O'Hanesian, M.A. Murphy, J.G. Schwartz, R.S. Serruys, P.W.J.C. Faxon, D.P. |
1996-01-01
|